Introduction {#s1}
============

It is estimated that gastric cancer is the fourth most common cancer in the world [@pone.0095371-Kamangar1]. In 2013, an estimated 21,600 new cases will occur and 10,990 cases will eventually die of their disease in the United States [@pone.0095371-Siegel1]. Despite advances in surgical treatment and chemotherapy, prognosis remains poor, particularly as most tumors are diagnosed late and in locally advanced or advanced stages. Currently, due to the ability to shrink cancerous lesions to increase R0 resection rate, neoadjuvant chemotherapy is recommended as the standard treatment for the management of locally advanced gastric cancer [@pone.0095371-Mezhir1]. Chemotherapy can also improve the outcome of unresectable gastric cancer. However, some studies suggest that only those patients who respond to neoadjuvant chemotherapy with tolerable toxicity will potentially benefit from this approach, while a proportion of patients fail to respond to neoadjuvant chemotherapy, or even progress during therapy [@pone.0095371-Ott1]--[@pone.0095371-Nashimoto1]. Therefore, predictive markers to identify those patients who would benefit from neoadjuvant chemotherapy are being actively sought.

To date, p53, the most studied gene, may be the primary candidate biomarker for predicting the response of gastric cancer to chemotherapy [@pone.0095371-Fareed1]. The gene encoding p53 is located on chromosome 17p and consists of 11 exons and 10 introns. It has important cellular functions, including in cell cycle regulation, apoptosis, and DNA repair [@pone.0095371-Lamb1], [@pone.0095371-Vousden1]. p53 is the gene most frequently mutated in human cancer, with alterations occurring in at least 50% of human malignancies, playing critical roles in their development [@pone.0095371-Tewari1]. Experimental evidence suggests that p53 status is associated with tumor response to genotoxic agents [@pone.0095371-Lowe1]--[@pone.0095371-Weller1]. However, data regarding the use of p53 status as a biological marker to predict the response of gastric cancer to chemotherapy are inconclusive [@pone.0095371-Fareed2]--[@pone.0095371-Yeh1]. Some studies found that patients with p53 mutations or overexpression had higher response rates to chemotherapy than those with normal p53 status; however, other reports drew different conclusions. Therefore, we conducted a meta-analysis to determine the value of p53 status in predicting response to chemotherapy in gastric cancer.

Materials and Methods {#s2}
=====================

Publication Search {#s2a}
------------------

Studies were identified by a computerized search of the PubMed, Embase, and Web of Science databases (up to Jun 8, 2013) using the following search terms: 'TP53', 'p53', 'p53 protein', 'p53 mutation', '17p13 gene', 'chemotherapy', 'chemoradiotherapy', and 'gastric cancer'. All potentially eligible studies were retrieved and their references were carefully researched to identify other eligible studies. When multiple studies of the same patient population were identified, the published report with the largest sample size was included.

Inclusion and Exclusion Criteria {#s2b}
--------------------------------

Studies selected in this meta-analysis fulfilled all of the following criteria: (a) studies evaluating p53 status for predicting the response to chemotherapy or chemoradiotherapy in gastric cancer; (b) studies involving clinical or pathological therapeutic response; (c) retrospective or prospective cohort study; (d) studies including adequate data to allow the estimation of a risk ratio (RR) with 95% confidence intervals (95% CI); and (e) studies in English or Chinese. Reviews, letters to the editor, and articles published in books were excluded.

Data Extraction and Definitions {#s2c}
-------------------------------

Using the inclusion criteria listed above, the following information was extracted from each study: the first author\'s surname, the publication year, the country of origin, the number of patients analyzed, the treatment, the methods of detection, p53 positive (overexpression or mutation) rate, the type of therapeutic response, the response criteria, and the main outcomes. This information was entered in tables showing the clinical or pathological response to chemotherapy with respect to p53 status. Data was carefully extracted from all eligible publications by two investigators. Any disagreement between the investigators was resolved by discussion until a consensus was reached. If they failed to reach an agreement, a third investigator was consulted to resolve the discrepancies.

As previously reported [@pone.0095371-Chen1], the definitions and standardizations for 'p53' and 'response to therapy' used in our study followed those of the study by Pakos et al. [@pone.0095371-Pakos1]. For consistency, we used 'p53 status' to refer to both gene and protein markers. p53 positive status indicates patients with high expression of p53 protein and/or mutations in the p53 gene. Good response was defined as complete response (CR) and partial response (PR), or grade 1b+2+3. Poor response was defined as stable disease (SD) and progress disease (PD), or grade 0+ 1a according to the guidelines for the clinical and pathologic studies on gastric carcinoma by the JRSGC (Japanese Research Society for Gastric Carcinoma), WHO (World Health Organization), or RECIST (Response Evaluation Criteria in Solid Tumors) criteria [@pone.0095371-Japanese1]--[@pone.0095371-WHO1]. The response classification is detailed in [Table 1](#pone-0095371-t001){ref-type="table"}.
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###### Criteria for response evaluation and standard definitions.

![](pone.0095371.t001){#pone-0095371-t001-1}

  Criteria                                                                                                                     Poor response                                                                                      Standard definition                                                                                                             Complete response
  --------------------------------------------------------------------------------------------------- ---------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------
                                                                                                                                                                                                                                     Good response                                                                
  WHO[@pone.0095371-WHO1]                                                                                           NC+PD, \<50% decrease in tumor load                                                                   PR+CR, \>50% decrease in tumor load                                                                                           CR, disappearance of all known disease
  RECIST[@pone.0095371-Therasse1]                                                                                     PD+SD, \<30% disease regression                                                                       PR+CR, \>30% disease regression                                                                                                  CR, 100% disease regression
  JRSGC[@pone.0095371-Japanese1], [@pone.0095371-Japanese2], [@pone.0095371-JapaneseGastricCancer1]    PD+SD, Grade 0+1,viable cancer cells account for more than 1/3                                         PR, Grade 2+3, viable cancer cells account for less than 1/3                                                                           CR, Grade 3, no residual viable tumor cells
  Sirak et al.[@pone.0095371-Sirak1]                                                                                    Inoperable tumor after NCRT                                Reduction of at least one T-stage level and/or finding of intense tumor regression on histopathologic examination                                               pCR, absence of tumor cells in the primary site
  Cascinu et al.[@pone.0095371-Cascinu1]                                                                                             NR                                 \>50% reduction in the visible tumor or complete disappearance of tumor but positive histology on biopsy of the previously involved area   Complete resolution of the endoscopically visible tumor and a negative biopsy of the original site of the tumor.
  Giatromanolaki et al.[@pone.0095371-Giatromanolaki1]                                                                25--49% reduction in tumor size                                                                       50--95% reduction in tumor size                                                                                              Disappearance of a measurable lesion

WHO, World Health Organization; RECIST, Response Evaluation Criteria in Solid Tumors; JRSGC, Japanese Research Society for Gastric Carcinoma; CR, complete response; PR, partial response; PD, progressive disease; SD, stable disease; NR, no record; NC, no change.

Statistical Analysis {#s2d}
--------------------

The software STATA version 12 (StataCorp, College Station, TX) was used to perform the data analysis. We assessed and quantified statistical heterogeneity for each pooled estimate using the I^2^ statistic, and p\>0.10 was defined as no heterogeneity. The pooled RR was calculated using a fixed-effects model (the Mantel--Haenszel method) or a random-effects model (the DerSimonian and Laird method), according to the heterogeneity results. Pooled analysis was performed using the Mantel-Haenszel model and reported as RR with 95% CIs. The significance of the pooled RR was determined by the z test and P\<0.05 was considered statistically significant. χ^2^ and z represented the test statistics of the I^2^ statistic for heterogeneity and z test for the significance of the pooled RR respectively. The Begg\'s funnel plot and Egger\'s test were employed to estimate potential publication bias. We also performed sensitivity analysis by omitting each study or specific studies to find potential outliers.

Results {#s3}
=======

Eligible Studies {#s3a}
----------------

Using different combinations of key terms, a total of 240 articles were retrieved by a literature search of the PubMed, Embase, and Web of Science databases. As indicated in the search flow diagram ([Figure 1](#pone-0095371-g001){ref-type="fig"}), 13 studies were finally included in this meta-analysis [@pone.0095371-Ott2]--[@pone.0095371-Yeh1], [@pone.0095371-Kamoshida1]--[@pone.0095371-Nakata1]. The characteristics of the eligible studies are summarized in [Table 2](#pone-0095371-t002){ref-type="table"}. Five used NCT, one used NCRT, and seven used CT ([Table 2](#pone-0095371-t002){ref-type="table"}). The sample sizes in eligible studies ranged from 23--131 patients (median  = 36, mean  = 43, standard deviation \[SD\]  = 28). Overall, the eligible studies included 564 patients. Five studies were conducted in European populations (167 patients) [@pone.0095371-Ott2], [@pone.0095371-Bataille1], [@pone.0095371-Sirak1], [@pone.0095371-Cascinu1], [@pone.0095371-Giatromanolaki1], whereas eight were in East Asian populations (397 patients) [@pone.0095371-Boku1]--[@pone.0095371-Yeh1], [@pone.0095371-Kamoshida1], [@pone.0095371-Boku2], [@pone.0095371-Kikuyama1], [@pone.0095371-Qu1], [@pone.0095371-Nakata1].

![Flow diagram illustrating the screening and selection process.](pone.0095371.g001){#pone-0095371-g001}
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###### Characteristics of studies included in the meta-analysis.
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  Author                                                   Year      Country       Cases   Treatment   Detection   p53 (%)    Response    Response criteria                Standard definition response             Response rate (%)  
  ------------------------------------------------------- ------ ---------------- ------- ----------- ----------- --------- ------------ ------------------- ------------ ------------------------------ --------- ------------------- -----
  Qu et al.[@pone.0095371-Qu1]                             2013       China         53        NCT         IHC        53%      clinical         RECIST           PD+SD                   PR                  CR             53%           0
  Sirak et al. [@pone.0095371-Sirak1]                      2009   Czech republic    36       NCRT         IHC        63%     pathologic     Sirak et al.      Inoperable           Down-staging             pCR            47%          22%
  Kamoshida et al. [@pone.0095371-Kamoshida1]              2007       Japan         38        NCT         IHC        39%     pathologic         JRSGC         grade 0+1a            grade 1b+2            grade 3          34%           0
  Boku et al. [@pone.0095371-Boku1]                        2007       Japan         131       CT          IHC        43%      clinical        WHO/JRSGC         PD+SD                 PR+CR                 NR             28%          NR
  Nagashima et al. [@pone.0095371-Nagashima1]              2005       Japan         55        CT          IHC        44%      clinical           WHO            PD+SD                 PR+CR                 NR             55%          NR
  Bataille et al. [@pone.0095371-Bataille1]                2003      Germany        25        NCT      IHC/gene      56%     pathologic         JRSGC         grade 0+1              grade 2              grade 3          44%          28%
  Ott et al. [@pone.0095371-Ott2]                          2003      Germany        48        NCT      IHC/gene      35%      clinical           WHO            PD+SD                   PR                  NR             40%          NR
  Giatromanolaki et al. [@pone.0095371-Giatromanolaki1]    2001       Greece        28        CT          IHC        25%      clinical    Kamoshida et al.        MR                    PR                  CR             36%          NR
  Kikuyama et al. [@pone.0095371-Kikuyama1]                2001       Japan         28        CT          IHC        46%      clinical        WHO/JRSGC         PD+SD                   PR                  CR             36%          4%
  Yeh et al. [@pone.0095371-Yeh1]                          1999       Taiwan        30        CT          IHC        20%      clinical           WHO            PD+SD                 PR+CR                 NR             50%          NR
  Boku et al. [@pone.0095371-Boku2]                        1998       Japan         39        CT          IHC        38%      clinical        WHO/JRSGC         PD+NC                 PR+CR                 NR             33%          NR
  Cascinu et al. [@pone.0095371-Cascinu1]                  1998       Italy         30        NCT         IHC        53%      clinical     Cascinu et al.         NR                    PR                  CR             40%          10%
  Nakata et al. [@pone.0095371-Nakata1]                    1998       Japan         23        CT          IHC        61%      clinical          JRSGC           PD+NC                   PR                  CR             43%          9%

CT, chemotherapy; NCT, neoadjuvant chemotherapy; NCRT, neoadjuvant chemoradiotherapy; IHC, immunohistochemistry; WHO, World Health Organization; RECIST, Response Evaluation Criteria in Solid Tumors; JRSGC, Japanese Research Society for Gastric Carcinoma; CR, complete response; PR, partial response; PD, progressive disease; SD, stable disease; NR, no record; NC, no change.

Relationship between p53 Status and Response to Chemotherapy in Gastric Cancer {#s3b}
------------------------------------------------------------------------------

Among the studies of gastric cancer patients who received chemotherapy, 13 (involving 564 patients) contributed data to the calculation of total OR (total OR  =  clinical OR + pathological OR). p53 positive status was significantly associated with improved total OR among patients treated with chemotherapy (RR = 0.704; 95% CI = 0.550--0.903; P = 0.006, [Figure 2](#pone-0095371-g002){ref-type="fig"}). With respect to studies reporting both clinical and pathological responses, the latter data was used, but the clinical response data was also examined with similar results (data not shown). p53 protein expression measured by immunohistochemistry (IHC) does not directly correspond to p53 mutation detected by gene sequencing [@pone.0095371-Ott2], [@pone.0095371-Bataille1]. As all studies included in this meta-analysis employed IHC-based protein detection, and only two employed both IHC and molecular genetic analysis, we adopted the data generated using IHC and also conducted statistical analysis for the molecular genetic data with similar results (RR = 0.720; 95% CI = 0.565--0.916; P = 0.008).

![Forest plots of RR estimated for the relationship between p53 status and good response among gastric cancer patients treated with chemotherapy.](pone.0095371.g002){#pone-0095371-g002}

Subgroup Analysis {#s3c}
-----------------

East Asian and European subgroups were also analyzed separately ([Table 3](#pone-0095371-t003){ref-type="table"}). p53 positive status was associated with improved response in gastric cancer patients who received chemotherapy in the East Asian subgroup (RR = 0.657, 95% CI = 0.488--0.884; P = 0.005; [Figure 3](#pone-0095371-g003){ref-type="fig"}). In the European subgroup, however, patients with p53 positive status tended to have high response rates to chemotherapy, but the results did not reach statistical significance (RR = 0.828, 95% CI = 0.525--1.305; P = 0.417).

![Forest plots of RR estimated for the relationship between p53 status and good response to chemotherapy in East Asian population with gastric cancer.](pone.0095371.g003){#pone-0095371-g003}
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###### Risk ratio for the association between p53 positive status and good response to chemotherapy.
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                              N         RR (95% CI)         z       P     χ^2^    Ph
  ------------------------- ------ ---------------------- ------ ------- ------ -------
  All studies                 13    0.704 (0.550--0.903)   2.77   0.006   9.25   0.681
  **Treatment**                                                                 
  CT                          7     0.729 (0.525--1.013)   1.89   0.059   1.55   0.956
  NCT                         5     0.644 (0.422--0.985)   2.03   0.042   7.56   0.109
  NCT+NCRT                    6     0.675 (0.463--0.985)   2.04   0.042   7.73   0.172
  **Area**                                                                      
  East Asian                  8     0.657 (0.488--0.884)   2.78   0.005   3.58   0.827
  European                    5     0.828 (0.525--1.305)   0.81   0.417   5.14   0.273
  **Type of measurement**                                                       
  IHC                         13    0.704 (0.550--0,903)   2.77   0.006   9.25   0.681
  IHC + gene                 11+2   0.720 (0.565--0.916)   2.67   0.008   9.91   0.624

Subgroup analysis was performed when at least five studies were in a subgroup.

N, number of studies; z, the test statistics of z test; P, p value of the z test; χ^2^, the test statistics of I^2^ statistic for heterogeneity; Ph, p value of the I^2^ statistic.

As five studies used NCT and one used NCRT, we also analyzed these data, and found that p53 positive status was associated with improved response in gastric cancer patients who received chemotherapy-based neoadjuvant treatment (RR = 0.675, 95% CI = 0.463--0.985, P = 0.042; [Figure 4](#pone-0095371-g004){ref-type="fig"}).

![Forest plots of RR estimated for the relationship between p53 status and good response to chemotherapy-based neoadjuvant treatment in patients with gastric cancer.](pone.0095371.g004){#pone-0095371-g004}

Publication Bias and Sensitivity Analysis {#s3d}
-----------------------------------------

The Begg\'s funnel plot and Egger\'s test were employed to estimate the publication bias of the literature included in this study. The shape of the funnel plot showed no obvious evidence of asymmetry ([Figure 5](#pone-0095371-g005){ref-type="fig"}), and the Egger\'s test indicated an absence of publication bias (P\>0.05). In addition, sensitivity analysis was conducted to assess the influence of individual studies on the summary effect. No individual study dominated this meta-analysis, and the removal of any single study had no significant effect on the overall results (data not shown).

![Funnel plot demonstrating that there was no obvious indication of publication bias for the outcome of good response.](pone.0095371.g005){#pone-0095371-g005}

Discussion {#s4}
==========

p53 status plays a key role in the response to many anticancer drugs. However, no consistent conclusion regarding the effect of p53 mutations on the sensitivity or resistance of gastric cancers to anticancer drugs has been reported. To date, the majority of available clinical reports involve small sample sizes, and were therefore unable to determine the value of p53 status for predicting the response to chemotherapy. Thus, we conducted a meta-analysis of 13 studies to systematically evaluate the association between p53 status and response to chemotherapy in a large population with gastric cancer.

Our results show that p53 positive status may predict response to chemotherapy in patients with gastric cancer. p53 positive status was associated with improved total OR. Stratification according to ethnicity showed that p53 positive status was significantly associated with increased OR in East Asian populations. In addition, with respect to neoadjuvant chemotherapy, our results showed that p53 positive status was associated with good response.

Although we did our utmost to perform a comprehensive analysis, some limitations remain in this study. Firstly, the meta-analysis may have been influenced by publication bias, as we limited the literature search to studies performed in English or Chinese, and we did not explore conference proceedings or abstract books. Although we attempted to identify all relevant data, some missing data are inevitable. However, using statistical methods, no publication bias was detected, suggesting that the pooled results are likely to be unbiased. Second, in this meta-analysis we used data derived from IHC-based detection of p53, which was performed in all included studies. However, the reported frequencies of positive p53 staining were variable, which may reflect the use of different antibodies, staining standards, criteria for positivity, and the inclusion of differently selected groups of gastric cancer patient groups. Third, the evaluation criterion of response to treatment among the studies was highly variable. Standardization is therefore of great importance for obtaining an accurate assessment of the clinical significance of p53 status. Despite our considerable efforts to standardize definitions, some variability among studies was inevitable. In addition, many other factors that could affect tumor sensitivity to treatment, such as tumor size, histological subtype, patient age, chemotherapy regimen, dose of chemotherapy or radiation, and courses of treatment, could not be obtained in sufficient detail for inclusion in statistical analyses. Fourth, as our analysis was observational in nature, we cannot exclude confounding as a potential explanation of the observed results.

Despite these limitations, this meta-analysis had several advantages. This is the first meta-analysis to evaluate the usefulness of p53 status for predicting the response of gastric cancer patients to chemotherapy. Also, as mentioned above, no publication bias was detected. The results showed that p53 status might be a useful predictive biomarker for evaluating response to chemotherapy in gastric cancer patients, especially in East Asian populations. However, future prospective studies with larger sample sizes, better study designs, and accurate detection methods are required to confirm our findings.
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